Literature DB >> 7441407

The disposition of indomethacin in preterm babies.

S J Yaffe, W F Friedman, D Rogers, P Lang, M Ragni, C Saccar.   

Abstract

Limited pharmacokinetic data are available concerning the disposition of indomethacin in preterm infants. Since oral absorption of the drug may be poor or incomplete, the current report provides pharmacokinetic data on 37 premature infants who received indomethacin intravenously. Each of these infants had a hemodynamically significant patent ductus arteriosus. Findings included variable serum indomethacin concentrations from four to 12 hours after a single dose of 0.2 mg/kg. Female preterm infants generally had lower serum drug values at 12 hours and beyond when compared to males. An extrauterine age dependence was found of serum indomethacin levels. Total body clearance, serum half lives and volumes of distribution also bore a direct relationship to extrauterine age. Thus, when indomethacin is administered shortly after birth, one may anticipate a longer duration of action after a single dose and a relatively greater risk of accumulation of the drug when more than one dose is required for treating a duct al patency.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441407     DOI: 10.1016/s0022-3476(80)80446-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

Review 1.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

2.  Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus.

Authors:  H W Seyberth; G Knapp; D Wolf; H E Ulmer
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

Review 3.  The pharmacological treatment of patent ductus arteriosus. A review of the evidence.

Authors:  R J Barst; W M Gersony
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

4.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

Authors:  J M Smyth; P S Collier; M Darwish; J S Millership; H L Halliday; S Petersen; J C McElnay
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

5.  Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents.

Authors:  B S Kaplan; I Restaino; D S Raval; R P Gottlieb; J Bernstein
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

6.  Variability of serum indomethacin concentrations after oral and intravenous administration to preterm infants.

Authors:  R Mrongovius; H Imbeck; L Wille; H Müller; H W Seyberth
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

7.  Multiple courses of indomethacin and neonatal outcomes in premature infants.

Authors:  Madhavi Sangem; Sumita Asthana; Sanjiv Amin
Journal:  Pediatr Cardiol       Date:  2007-12-18       Impact factor: 1.655

8.  Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates.

Authors:  P Colditz; D Murphy; P Rolfe; A R Wilkinson
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

Review 9.  Nonsteroidal anti-inflammatory agents in neonates.

Authors:  John L Morris; David A Rosen; Kathleen R Rosen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Intravenous indomethacin for patent ductus arteriosus.

Authors:  I J Smith; I Goss; P J Congdon
Journal:  Arch Dis Child       Date:  1984-06       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.